Mayank Mamtani Analyst Performance

Senior Managing Director & Group Head of Healthcare at B. Riley

Mayank Mamtani is a stock analyst at B. Riley in the medical sector, covering 40 publicly traded companies. Over the past year, Mayank Mamtani has issued 17 stock ratings, including strong buy, buy, and hold recommendations. While full access to Mayank Mamtani's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mayank Mamtani's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 164 Last 6 Years
Buy Recommendations: 90.38% 141 Buy Ratings
Companies Covered: 40 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	1.3%	2 ratings
Buy	89.1%	139 ratings
Hold	9.6%	15 ratings
Sell	0.0%	0 ratings

Out of 156 total stock ratings issued by Mayank Mamtani at B. Riley, the majority (89.1%) have been Buy recommendations, followed by 9.6% Hold and 1.3% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
ALNA
Mar 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
NVAX
Apr 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	95.0% of companies on NASDAQ	38 companies
NYSEAMERICAN	2.5% of companies on NYSEAMERICAN	1 company
OTCMKTS	2.5% of companies on OTCMKTS	1 company

Mayank Mamtani, an analyst at B. Riley, currently covers 40 companies listed on NASDAQ, NYSEAMERICAN and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 40 companies	100.0%

Mayank Mamtani of B. Riley specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 18 companies	45.0%
MED - DRUGS 9 companies	22.5%
PHARMACEUTICAL PREPARATIONS 8 companies	20.0%
BIOTECHNOLOGY 3 companies	7.5%
MED PRODUCTS 1 company	2.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	2.5%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
NKTR Nektar Therapeutics	9/23/2025	Boost Price Target	$58.63	$105.00	Buy
HROW Harrow	9/23/2025	Boost Price Target	$48.61	$70.00	Buy
CYTK Cytokinetics	9/22/2025	Boost Price Target	$49.04	$80.00	Buy
TGTX TG Therapeutics	9/17/2025	Boost Price Target	$32.51	$55.00	Buy
TBPH Theravance Biopharma	9/12/2025	Initiated Coverage	$13.70	$28.00	Buy
TBPH Theravance Biopharma	9/11/2025	Upgrade	$14.30		Strong-Buy
ACTU Actuate Therapeutics	8/26/2025	Initiated Coverage	$7.98	$20.00	Buy
ACTU Actuate Therapeutics	8/25/2025	Initiated Coverage	$8.19	$20.00	Buy
ALT Altimmune	8/13/2025	Lower Price Target	$3.62	$18.00	Buy
MNOV MediciNova	6/16/2025	Upgrade	$1.31	$5.00	Strong-Buy
MGNX MacroGenics	5/20/2025	Lower Price Target	$1.57	$3.00	Neutral
HROW Harrow	4/1/2025	Lower Price Target	$25.23	$65.00	Buy
VXRT Vaxart	3/27/2025	Lower Price Target	$0.45	$2.00	Buy
TRVI Trevi Therapeutics	3/19/2025	Reiterated Rating	$6.69	$20.00	Buy
LCTX Lineage Cell Therapeutics	3/14/2025	Lower Price Target	$0.52	$3.00	Buy
DNLI Denali Therapeutics	3/5/2025	Reiterated Rating	$16.06	$35.00	Buy
ARWR Arrowhead Pharmaceuticals	2/14/2025	Reiterated Rating	$19.75	$38.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.